GlassScriptPhysician profile
Ifeoluwa Ogunbadeniyl
NPI 1912392754
$2,729.60
in general payments reported to CMS, 2019-2025
29 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $242 · 2021: $483 · 2022: $317 · 2023: $336 · 2024: $532 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $313.55 | 2019-2025 | Veozah |
| Lilly USA, LLC | $276.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $257.65 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $189.32 | 2021-2024 | Vraylar |
| Abbott Laboratories | $144.90 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $139.69 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.59 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $105.89 | 2020-2022 | |
| Pfizer INC. | $97.41 | 2019-2024 | |
| Dexcom, INC. | $89.54 | 2023-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $72.51 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $63.09 | 2022-2025 | |
| Amgen INC. | $59.89 | 2020-2025 | Repatha |
| Hologic Sales and Service, LLC | $51.09 | 2022-2024 | Aptima |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.61 | 2025 | |
| Exact Sciences Corporation | $42.67 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $42.60 | 2021-2025 | Gardasil 9 |
| Amarin Pharma, INC. | $38.11 | 2020 | |
| Viiv Healthcare Company | $24.46 | 2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $22.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.65 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.00 | 2021 | |
| Optinose US, INC. | $20.98 | 2021 | |
| Esperion Therapeutics, INC. | $17.30 | 2021 | |
| Boston Scientific Corporation | $15.30 | 2019 | |
| Scynexis, INC. | $12.37 | 2022 | |
| Genentech USA, INC. | $11.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ifeoluwa Ogunbadeniyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.